Assignee
ABREXA PHARMACEUTICALS INC
US·5 granted patents·4 pending applications·2 citations·filing 2019–2025
Top patents by PatentIndex Score
9 records- 0173US10968167B22,2,2-trifluoroacetic acid 1-(2,4-Dimethylphenyl)-2-[(3-methoxyphenyl)methylene] hydrazide polymorphs and method of making the sameABREXA PHARMACEUTICALS INC·Filed 2019·Granted Apr 6, 2021·2 cites·21 claims
- 0267US11584711B22,2,2-trifluoroacetic acid 1-(2,4-dimethylphenyl)-2-[(3-methoxyphenyl)methylene] method of making the sameABREXA PHARMACEUTICALS INC·Filed 2021·Granted Feb 21, 2023·0 cites·15 claims
- 0364US2024277640A1Compositions and methods for prevention and treatment of coronavirus and related disordersABREXA PHARMACEUTICALS INC·Filed 2024·Application pending·0 cites
- 0461US11938104B1Compositions and methods for prevention and treatment of coronavirus and related disordersABREXA PHARMACEUTICALS INC·Filed 2022·Granted Mar 26, 2024·0 cites·3 claims
- 0557US2026076926A1Compounds for use in organ preservation and organ transplantationABREXA PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 0652US12496281B2Compounds for prevention and treatment of hemorrhage and vasculature instabilityABREXA PHARMACEUTICALS INC·Filed 2021·Granted Dec 16, 2025·0 cites·15 claims
- 0743US12357596B2Compounds for prevention and treatment of obesity and related disordersABREXA PHARMACEUTICALS INC·Filed 2020·Granted Jul 15, 2025·0 cites·18 claims
- 0839US2021361598A1Compounds for prevention and treatment of post-intensive care cognitive dysfunction and cognitive dysfunction resulting from respiratory distressABREXA PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 0937US2022273590A1Compounds for prevention and treatment of post-operative cognitive dysfunctionABREXA PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ABREXA PHARMACEUTICALS INC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →